Yuanfei Yao

1.7k total citations · 2 hit papers
49 papers, 1.3k citations indexed

About

Yuanfei Yao is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Yuanfei Yao has authored 49 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 18 papers in Oncology and 16 papers in Cancer Research. Recurrent topics in Yuanfei Yao's work include Cancer-related molecular mechanisms research (8 papers), MicroRNA in disease regulation (6 papers) and Nanoplatforms for cancer theranostics (5 papers). Yuanfei Yao is often cited by papers focused on Cancer-related molecular mechanisms research (8 papers), MicroRNA in disease regulation (6 papers) and Nanoplatforms for cancer theranostics (5 papers). Yuanfei Yao collaborates with scholars based in China, United States and France. Yuanfei Yao's co-authors include Yanqiao Zhang, Jiani Yang, Ming Shi, Bojun Wang, Huan Nie, Yaqian Du, Piaoping Yang, Fei Zhan, Youpeng Qu and Fei He and has published in prestigious journals such as Advanced Materials, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Yuanfei Yao

47 papers receiving 1.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer

2021 170 citations Chao Liu, Ruiqi Liu et al. Journal for ImmunoTherapy of Cancer profile →
PGLYRP2 drives hepatocyte-intrinsic innate immunity by trapping and clearing hepatitis B virus

2025 17 citations Yuanfei Yao et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yuanfei Yao China	20	682	334	328	308	181	49	1.3k
Guangyu Yao China	20	638 0.9×	294 0.9×	359 1.1×	226 0.7×	346 1.9×	45	1.4k
Hongmei Zheng China	21	712 1.0×	435 1.3×	261 0.8×	155 0.5×	163 0.9×	67	1.2k
Yi Qing China	24	887 1.3×	214 0.6×	318 1.0×	168 0.5×	174 1.0×	57	1.4k
Xiangjun Meng China	20	781 1.1×	290 0.9×	384 1.2×	176 0.6×	139 0.8×	41	1.4k
Chun‐Chia Cheng Taiwan	21	419 0.6×	187 0.6×	260 0.8×	171 0.6×	156 0.9×	53	1.1k
Sang‐Yeob Kim South Korea	24	797 1.2×	262 0.8×	440 1.3×	271 0.9×	266 1.5×	81	1.6k
Sufang Zhou China	20	690 1.0×	153 0.5×	240 0.7×	285 0.9×	187 1.0×	69	1.2k
Qijie Zhao China	17	593 0.9×	375 1.1×	354 1.1×	290 0.9×	122 0.7×	23	1.2k
Huan Deng China	21	756 1.1×	319 1.0×	237 0.7×	251 0.8×	221 1.2×	48	1.3k
Branislava Janic United States	23	547 0.8×	193 0.6×	194 0.6×	203 0.7×	202 1.1×	50	1.3k

Countries citing papers authored by Yuanfei Yao

Since Specialization

Citations

This map shows the geographic impact of Yuanfei Yao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuanfei Yao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuanfei Yao more than expected).

Fields of papers citing papers by Yuanfei Yao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuanfei Yao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuanfei Yao. The network helps show where Yuanfei Yao may publish in the future.

Co-authorship network of co-authors of Yuanfei Yao

This figure shows the co-authorship network connecting the top 25 collaborators of Yuanfei Yao. A scholar is included among the top collaborators of Yuanfei Yao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuanfei Yao. Yuanfei Yao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Rui, Yuanfei Yao, Yang Lü, et al.. (2025). Constructing flexible sub-nanometer ferroelectric catalyst to overcome heterocatalytic kinetic barriers for enhanced catalytic and immuno-therapy. Nature Communications. 17(1). 404–404.

Li, Hengzhen, Chao Liu, Xiaona Fan, et al.. (2024). VDR promotes pancreatic cancer progression in vivo by activating CCL20-mediated M2 polarization of tumor associated macrophage. Cell Communication and Signaling. 22(1). 224–224. 11 indexed citations

Yang, Jiani, Yaqian Du, Yuanfei Yao, et al.. (2024). Employing Piezoelectric Mg ²⁺ ‐Doped Hydroxyapatite to Target Death Receptor‐Mediated Necroptosis: A Strategy for Amplifying Immune Activation. Advanced Science. 11(13). e2307130–e2307130. 22 indexed citations

Liu, Ruiqi, Shuling Han, Chunhui Zhang, et al.. (2024). Targeting Arachidonic Acid Metabolism Enhances Immunotherapy Efficacy in ARID1A-Deficient Colorectal Cancer. Cancer Research. 85(5). 925–941. 12 indexed citations

Yang, Rui, Bojun Wang, Luying Cui, et al.. (2024). Mevalonate kinase inhibits anti-tumor immunity by impairing the tumor cell-intrinsic interferon response in microsatellite instability colorectal cancer. Oncogene. 44(14). 944–957. 5 indexed citations

Guan, Xin, Ruiqi Liu, Bojun Wang, et al.. (2024). Inhibition of HDAC2 sensitises antitumour therapy by promoting NLRP3/GSDMD‐mediated pyroptosis in colorectal cancer. Clinical and Translational Medicine. 14(6). e1692–e1692. 24 indexed citations

Wang, Xinxin, Jianmin Zhou, Yanlin Zhu, et al.. (2024). Dual-doped metalloporphyrin MOFs-based nanoagent increases low-dose radiotherapy efficacy by apoptosis-ferroptosis for hepatocellular carcinoma. Chemical Engineering Journal. 501. 157645–157645. 6 indexed citations

Fang, Lin, Yang Yao, Yang Yao, et al.. (2023). China special issue on gastrointestinal tumors‐Regulatory‐immunoscore—A novel indicator to guide precision adjuvant chemotherapy in colorectal cancer. International Journal of Cancer. 153(11). 1904–1915. 6 indexed citations

Sun, Haoxiu, Chao Liu, Fang Han, et al.. (2023). The regulation loop of MARVELD1 interacting with PARP1 in DNA damage response maintains genome stability and promotes therapy resistance of cancer cells. Cell Death and Differentiation. 30(4). 922–937. 16 indexed citations

10.

Lü, Xiaolin, Ruiqi Liu, Luying Cui, et al.. (2023). ACVRL1 drives resistance to multitarget tyrosine kinase inhibitors in colorectal cancer by promoting USP15-mediated GPX2 stabilization. BMC Medicine. 21(1). 366–366. 8 indexed citations

11.

Wu, Dehai, Guanqun Liao, Yuanfei Yao, et al.. (2023). Downregulated Acetyl-CoA Acyltransferase 2 Promoted the Progression of Hepatocellular Carcinoma and Participated in the Formation of Immunosuppressive Microenvironment. Journal of Hepatocellular Carcinoma. Volume 10. 1327–1339. 2 indexed citations

12.

Yao, Yuanfei, et al.. (2022). Efficacy of Different Number of XELOX or SOX Chemotherapy Cycles After D2 Resection for Stage III Gastric Cancer. Journal of the Korean Gastric Cancer Association. 22(2). 107–107.

13.

Liu, Chao, Ruiqi Liu, Bojun Wang, et al.. (2021). Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer. Journal for ImmunoTherapy of Cancer. 9(1). e001895–e001895. 170 indexed citations breakdown →

14.

Zhang, Xiaohan, Xiuyun Shi, Xin Lu, et al.. (2020). Novel Metabolomics Serum Biomarkers for Pancreatic Ductal Adenocarcinoma by the Comparison of Pre-, Postoperative and Normal Samples. Journal of Cancer. 11(16). 4641–4651. 15 indexed citations

15.

Cui, Ying, Jinghao Wang, Shanshan Liu, et al.. (2019). miR‐216a promotes breast cancer cell apoptosis by targeting PKCα. Fundamental and Clinical Pharmacology. 33(4). 397–404. 23 indexed citations

16.

Zhang, Chunbin, Fang Han, Ming Shi, et al.. (2019). MARVELD1 interacting with catalase regulates reactive oxygen species metabolism and mediates the sensitivity to chemotherapeutic drugs in epithelial tumors of the reproductive system. Molecular Carcinogenesis. 58(8). 1410–1426. 8 indexed citations

17.

Han, Fang, Shuai Qu, Yuanfei Yao, et al.. (2018). MARVELD1 depletion leads to dysfunction of motor and cognition via regulating glia-dependent neuronal migration during brain development. Cell Death and Disease. 9(10). 999–999. 12 indexed citations

18.

Zhang, Fan, Changsong Wang, Yinghua Cui, et al.. (2016). Effects of Propofol on Several Membrane Characteristics of Cervical Cancer Cell Lines. Cellular Physiology and Biochemistry. 40(1-2). 172–182. 16 indexed citations

19.

Yao, Yuanfei, Ming Shi, Shanshan Liu, et al.. (2015). MARVELD1 modulates cell surface morphology and suppresses epithelial–mesenchymal transition in non‐small cell lung cancer. Molecular Carcinogenesis. 55(11). 1714–1727. 14 indexed citations

20.

Shi, Ming, et al.. (2014). MAP1S Controls Breast Cancer Cell TLR5 Signaling Pathway and Promotes TLR5 Signaling-based Tumor Suppression. PLoS ONE. 9(1). e86839–e86839. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact